BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9288791)

  • 1. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
    Daly JM; Jannot CB; Beerli RR; Graus-Porta D; Maurer FG; Hynes NE
    Cancer Res; 1997 Sep; 57(17):3804-11. PubMed ID: 9288791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Daly JM; Olayioye MA; Wong AM; Neve R; Lane HA; Maurer FG; Hynes NE
    Oncogene; 1999 Jun; 18(23):3440-51. PubMed ID: 10376522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
    Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
    Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
    Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
    Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.
    Piepkorn M; Predd H; Underwood R; Cook P
    Arch Dermatol Res; 2003 Jul; 295(3):93-101. PubMed ID: 12768307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
    Graus-Porta D; Beerli RR; Daly JM; Hynes NE
    EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
    Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
    Bacus SS; Gudkov AV; Zelnick CR; Chin D; Stern R; Stancovski I; Peles E; Ben-Baruch N; Farbstein H; Lupu R
    Cancer Res; 1993 Nov; 53(21):5251-61. PubMed ID: 8106145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells.
    Ram TG; Kokeny KE; Dilts CA; Ethier SP
    J Cell Physiol; 1995 Jun; 163(3):589-96. PubMed ID: 7775601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB2 and EGFR are downmodulated during the differentiation of 3T3-L1 preadipocytes.
    Pagano E; Calvo JC
    J Cell Biochem; 2003 Oct; 90(3):561-72. PubMed ID: 14523990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells.
    Uckun FM; Narla RK; Jun X; Zeren T; Venkatachalam T; Waddick KG; Rostostev A; Myers DE
    Clin Cancer Res; 1998 Apr; 4(4):901-12. PubMed ID: 9563884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
    EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
    Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
    Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
    Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.